Fennec Pharmaceuticals Ord Shs T.FRX

Alternate Symbol(s): FENC

Healthcare Biotechnology

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on its product candidate PEDMARK. It sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is a Food and Drug Administration approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. It has established Fennec HEARS, a single source program designed to connect PEDMARK patients.

TSX:FRX - Post by User

Fennec Pharmaceuticals Ord Shs > IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

<< Previous

Bullboard Posts

Next >>

Comment by willyk3on Dec 09, 2021 9:46am

252 Views

Post# 34214053

RE:IS THIRD TIME THE CHARM FOR FENNEC PHARMACEUTICALS?

Absolute dud The fact that they failed at the manufacturing revisions shows that they and their mfg partner are incompetant at this aspect of the process. Wonder who that is ?

Drug works...allbeit a dangerous potion...fraught with potential lawsuits if improperly doled out

Maybe they should give Jan a call at Acasti...she sure knows how to execute...LOL

<< Previous

Bullboard Posts

Next >>

E3 inches closer to Alberta's first lithium production plant